Jupiter Neurosciences (JUNS)
0.24
-0.02 (7.69%)
Upcoming Events
Latest Headlines
Form 424B3 JUPITER NEUROSCIENCES,
June 5, 2026 4:32 PM - SEC Filing
Form 8-K JUPITER NEUROSCIENCES, For: Jun 02
June 5, 2026 4:31 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Brady Allison W
June 5, 2026 8:24 AM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Hayward Marshall A.
June 4, 2026 9:04 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Elmasri Saleem
June 4, 2026 9:02 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Kampf Julie B.
June 4, 2026 9:02 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Silva Alison D.
June 4, 2026 9:02 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: ROSEN CHRISTER
June 4, 2026 9:02 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Hemmerly Nicholas H.
June 4, 2026 9:02 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Weis Holger
June 4, 2026 8:47 PM - SEC Filing
Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Rosen Alexander Gustaf Erik
June 4, 2026 8:47 PM - SEC Filing
Jupiter Neurosciences begins patient enrollment for Parkinson's trial
May 27, 2026 7:30 AM - StreetInsider
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
May 27, 2026 7:30 AM - StreetInsider
Jupiter Neurosciences closes $2 million registered direct offering
May 26, 2026 12:00 PM - StreetInsider
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
May 26, 2026 12:00 PM - StreetInsider
Jupiter Neurosciences closes $2 million registered direct offering
May 21, 2026 5:15 PM - StreetInsider
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
May 21, 2026 5:15 PM - StreetInsider
Jupiter Neurosciences prices $2 million registered direct offering
May 20, 2026 2:38 PM - StreetInsider
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
May 20, 2026 2:38 PM - StreetInsider
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
May 20, 2026 8:15 AM - Globe NewsWire
Jupiter Neurosciences secures $100M term sheet for MDMA therapeutic rights
May 20, 2026 7:44 AM - StreetInsider
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
May 20, 2026 7:38 AM - Globe NewsWire
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
May 4, 2026 11:32 AM - StreetInsider
Jupiter Neurosciences (JUNS) files $100M mixed shelf
April 16, 2026 6:12 AM - StreetInsider
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
April 13, 2026 8:02 PM - StreetInsider
Jupiter Neurosciences names two advisors for Nugevia consumer line
April 7, 2026 12:35 PM - StreetInsider
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
April 7, 2026 12:35 PM - Globe NewsWire
Jupiter Neurosciences adds two advisors to Nugevia board
April 7, 2026 8:14 AM - StreetInsider
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
April 7, 2026 8:14 AM - StreetInsider
Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream
April 1, 2026 7:00 AM - Globe NewsWire
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
March 31, 2026 12:00 PM - StreetInsider
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026 8:35 AM - StreetInsider
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:22 AM - StreetInsider
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:21 AM - Globe NewsWire
Full Article List
